These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38675218)

  • 1. Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives.
    Bhuniya S; Vrettos EI
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
    Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
    Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Li Y; Zhao L; Li XF
    Front Oncol; 2021; 11():700407. PubMed ID: 34395270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Specific Oxidoreductases in the Design of Hypoxia-Activated Prodrugs and Fluorescent Turn off-on Probes for Hypoxia Imaging.
    Janczy-Cempa E; Mazuryk O; Kania A; Brindell M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma.
    Huynh KN; Rao S; Roth B; Bryan T; Fernando DM; Dayyani F; Imagawa D; Abi-Jaoudeh N
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
    Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
    Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment.
    Yuan X; Xie Z; Zou T
    Bioorg Chem; 2024 Mar; 144():107161. PubMed ID: 38306826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Baran N; Konopleva M
    Clin Cancer Res; 2017 May; 23(10):2382-2390. PubMed ID: 28137923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reductive Activity and Mechanism of Hypoxia- Targeted AGT Inhibitors: An Experimental and Theoretical Investigation.
    Xiao W; Sun G; Fan T; Liu J; Zhang N; Zhao L; Zhong R
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts.
    Shahpouri M; Adili-Aghdam MA; Mahmudi H; Jaymand M; Amoozgar Z; Akbari M; Hamblin MR; Jahanban-Esfahlan R
    J Control Release; 2023 Jan; 353():1002-1022. PubMed ID: 36516901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
    Anduran E; Aspatwar A; Parvathaneni NK; Suylen D; Bua S; Nocentini A; Parkkila S; Supuran CT; Dubois L; Lambin P; Winum JY
    Molecules; 2020 May; 25(10):. PubMed ID: 32443462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting tumors with hypoxia-activated cytotoxins.
    Ahn GO; Brown M
    Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
    Zhao XB; Gao K; Shi YP
    Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
    Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
    Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
    Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
    Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.